Bicara Therapeutics (BCAX) News Today $12.11 +0.23 (+1.94%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from AnalystsShares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have earned an average recommendation of "Buy" from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recoJanuary 20 at 4:21 AM | marketbeat.comBicara Therapeutics Initiates Corporate Presentation on Promising Corporate StrategyJanuary 20 at 2:04 AM | americanbankingnews.comBicara Therapeutics Inc. (BCAX)January 17, 2025 | uk.finance.yahoo.comBicara Therapeutics (NASDAQ:BCAX) Stock Quotes, Forecast and News SummaryJanuary 17, 2025 | benzinga.comBicara Therapeutics (NASDAQ:BCAX) Stock Price Down 4.1% - Here's WhyBicara Therapeutics (NASDAQ:BCAX) Stock Price Down 4.1% - Here's What HappenedJanuary 16, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week Low - Here's What HappenedBicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week Low - Here's WhyJanuary 13, 2025 | marketbeat.comGeode Capital Management LLC Takes $1.24 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Geode Capital Management LLC bought a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 48,639 shares of the company's stock, valued at approximately $1,239,000.January 10, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Reaches New 52-Week Low - Here's What HappenedJanuary 6, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Shares Down 2.9% - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 2.9% - Here's WhyJanuary 2, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Trading Down 5.9% - Here's What HappenedBicara Therapeutics (NASDAQ:BCAX) Trading Down 5.9% - Here's What HappenedDecember 27, 2024 | marketbeat.comBicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of "Buy" from AnalystsBicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has assignedDecember 26, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Trading 5.5% Higher - Still a Buy?Bicara Therapeutics (NASDAQ:BCAX) Trading 5.5% Higher - What's Next?December 23, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Shares Gap Down - Should You Sell?Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down - Here's WhyDecember 20, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Reaches New 12-Month Low - Should You Sell?Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low - Should You Sell?December 19, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Stock Price Down 5.8% - Time to Sell?Bicara Therapeutics (NASDAQ:BCAX) Shares Down 5.8% - What's Next?December 18, 2024 | marketbeat.comWellington Management Group LLP Takes $19.46 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Wellington Management Group LLP bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 763,943 shares of the company's stocDecember 14, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low - Time to Sell?Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low - Here's What HappenedDecember 13, 2024 | marketbeat.comPoint72 Asset Management L.P. Purchases New Stake in Bicara Therapeutics Inc. (NASDAQ:BCAX)Point72 Asset Management L.P. purchased a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 371,962 shares of the company's stock,December 8, 2024 | marketbeat.comJanus Henderson Group PLC Invests $30.33 Million in Bicara Therapeutics Inc. (NASDAQ:BCAX)Janus Henderson Group PLC bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,188,191 shares of the company's stock, valued at approximatDecember 7, 2024 | marketbeat.comWalleye Capital LLC Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Walleye Capital LLC acquired a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,780 shares of the cDecember 7, 2024 | marketbeat.com2,273,792 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Fmr LLCFmr LLC bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 2,273,792 shares of the company's stock, valued at approximately $57,913December 7, 2024 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Bicara Therapeutics (BCAX) with Buy RecommendationDecember 7, 2024 | msn.comPromising Potential of Bicara Therapeutics’ Ficerafusp Alfa: A Buy Rating Supported by Innovative Dual-Targeting and Positive Trial ResultsDecember 6, 2024 | markets.businessinsider.comBicara Therapeutics (NASDAQ:BCAX) Coverage Initiated by Analysts at HC WainwrightHC Wainwright initiated coverage on shares of Bicara Therapeutics in a report on Friday. They set a "buy" rating and a $42.00 price objective on the stock.December 6, 2024 | marketbeat.comSamsara BioCapital LLC Makes New $891,000 Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)Samsara BioCapital LLC purchased a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 35,000 shares of the company's stock, valued at approximately $891,000. Samsara BioCapital LLCDecember 5, 2024 | marketbeat.com6,955,993 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by RA Capital Management L.P.RA Capital Management L.P. acquired a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 6,955,993 shares of the company's stock, valued at approximately $177,169December 5, 2024 | marketbeat.comPoint72 DIFC Ltd Takes $1.42 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Point72 DIFC Ltd bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 55,757 shares of the company's stock, valDecember 5, 2024 | marketbeat.comMaven Securities LTD Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)Maven Securities LTD bought a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 50,000 shares of the company's stock, valuedDecember 5, 2024 | marketbeat.comBaker BROS. Advisors LP Invests $21.23 Million in Bicara Therapeutics Inc. (NASDAQ:BCAX)Baker BROS. Advisors LP purchased a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 833,333 shares of the company's stock, valued at aDecember 2, 2024 | marketbeat.comBicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Recommendation of "Buy" by AnalystsBicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has been given an average rating of "Buy" by the six analysts that are currently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the companDecember 1, 2024 | marketbeat.com1,657,600 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Braidwell LPBraidwell LP bought a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,657,600 shares of the company's stock, valued at approximately $42,219,000. BraidweNovember 29, 2024 | marketbeat.comVestal Point Capital LP Buys Shares of 425,000 Bicara Therapeutics Inc. (NASDAQ:BCAX)Vestal Point Capital LP bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 425,000 shares of the company's stock, valued at approximatelyNovember 29, 2024 | marketbeat.comBicara Therapeutics initiated with a Not Rated at Goldman SachsNovember 20, 2024 | markets.businessinsider.comFirst Turn Management LLC Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)First Turn Management LLC purchased a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 562,391 shares of the company's stocNovember 19, 2024 | marketbeat.comFY2024 EPS Estimates for BCAX Cut by Cantor FitzgeraldBicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2024 earnings estimates for Bicara Therapeutics in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will post earningsNovember 18, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Shares Down 6.2% - Here's WhyBicara Therapeutics (NASDAQ:BCAX) Stock Price Down 6.2% - Here's What HappenedNovember 15, 2024 | marketbeat.comPromising Prospects for Bicara Therapeutics: Buy Rating Reinforced by Strong Lead Asset and Strategic PositionNovember 13, 2024 | markets.businessinsider.comBicara Therapeutics: Newly Minted Upsized IPO With Positive Early DataNovember 12, 2024 | seekingalpha.comBicara Therapeutics Inc.: Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | finanznachrichten.deBicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comBicara Therapeutics to Present at the Stifel 2024 Healthcare ConferenceNovember 11, 2024 | globenewswire.comBicara Therapeutics initiated with a Buy at Rodman & RenshawNovember 7, 2024 | markets.businessinsider.comRODMAN&RENSHAW Upgrades Bicara Therapeutics (NASDAQ:BCAX) to "Strong-Buy"RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a "strong-buy" rating in a research report on Tuesday.November 6, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Coverage Initiated at Rodman & RenshawRodman & Renshaw began coverage on shares of Bicara Therapeutics in a research note on Tuesday. They set a "buy" rating and a $48.00 price target on the stock.November 5, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Trading Up 7.9% - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Trading 7.9% Higher - Time to Buy?October 18, 2024 | marketbeat.comBicara Therapeutics Inc.'s Quiet Period Will End on October 23rd (NASDAQ:BCAX)Bicara Therapeutics' (NASDAQ:BCAX - Get Free Report) quiet period will expire on Wednesday, October 23rd. Bicara Therapeutics had issued 17,500,000 shares in its IPO on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. During the company's quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.October 16, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Sets New 52-Week Low - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Sets New 52-Week Low - Here's WhyOctober 10, 2024 | marketbeat.comBicara Therapeutics Inc. (NASDAQ:BCAX) to Post FY2024 Earnings of ($1.61) Per Share, Cantor Fitzgerald ForecastsBicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Bicara Therapeutics in a note issued to investors on Tuesday, October 8th. Cantor Fitzgerald analyst E. Schmidt expects thatOctober 10, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Trading Down 3.5% - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 3.5% - Here's WhyOctober 9, 2024 | marketbeat.comLast Week's 3 Biotech IPOs Prompt Huge Insider BuyingSeptember 22, 2024 | 247wallst.com Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAX Media Mentions By Week BCAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCAX News Sentiment▼0.150.46▲Average Medical News Sentiment BCAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCAX Articles This Week▼52▲BCAX Articles Average Week Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DNLI News Today MRUS News Today ZLAB News Today SWTX News Today BHC News Today CPRX News Today RXRX News Today TWST News Today GMTX News Today HCM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCAX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCAX Stock Alerts